Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.03%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.12 per share when it actually produced earnings of $3.11, delivering a surprise of 46. ...

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterl ...

文章核心观点 - 公司第一季度收入增长5%至2.895亿美元 [1][2] - 公司诊断和空间生物学业务收入增长14% [10] - 公司细胞和基因疗法业务表现强劲 [3] 财务摘要 - 第一季度GAAP每股收益为0.21美元,上年同期为0.31美元 [7] - 第一季度调整后每股收益为0.42美元,上年同期为0.41美元 [8] - 第一季度GAAP营业利润率为13.8%,上年同期为20.2% [7] - 第一季度调整后营业利润率为29.0%,上年同期为31.4% [8] 业务分部表现 - 蛋白质科学业务收入持平,毛利率下降主要受产品组合和激励计划恢复影响 [9] - 诊断和空间生物学业务收入增长14%,毛利率提升主要受益于规模效应和生产效率 [10] 其他信息 - 公司将于10月30日召开财报电话会议 [5] - 公司持续专注于为客户提供创新解决方案,推动科学和医疗事业发展 [5]

文章核心观点 - 医疗设备行业第三季度业绩预计将保持强劲增长,主要得益于医疗产品和服务需求持续以及有利的定价策略,抵消了地缘政治问题、高利息费用和医疗人员短缺带来的不利影响[1][3] - 医疗行业整体第三季度收益预计增长3.5%,收入增长8.8%,但低于第二季度的19.3%收益增长和8.4%收入增长,主要受到中东问题导致的油价危机和供应中断以及汇率不利影响[2][3] - 医疗设备行业正面临人员短缺、医疗供应成本上升、地缘政治环境恶化导致的供应链瓶颈等挑战,这些都对公司利润率造成压力[7] - 诊断测试公司的新冠检测需求大幅下降[8] 行业关键要点 - 医疗设备行业正在快速采用生成式人工智能和数字疗法,这将推动行业创新和投资[5][6] - 人口老龄化、健康意识提高和医疗服务可及性提升等宏观趋势为行业发展创造有利条件[6] - 赞美生物(ZBH)的髋关节和膝关节业务有望在第三季度表现良好[9][10] - 百力瑞(BIO)的生命科学业务受到生物技术和生物制药市场疲软的不利影响,但临床诊断业务有望增长[12] - 百泰克(TECH)的细胞和基因疗法以及空间生物学业务保持良好增长势头[14]

CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET. To schedule a meeting wi ...

HOLMDEL, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication, announced that it has received a $910,000 order from a long-term financial services customer to upgrade to BIO-key's "fingerprint only" Biometric Customer Identification Technology. The technology enhancem ...

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences. 2024 ThinkEqui ...

SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence ( ...

文章核心观点 - Bio-Rad Laboratories, Inc.即将于10月30日发布2024年第三季度业绩报告 [1] - 公司上一季度的调整后每股收益超出市场预期46.7% [1] - 公司过去4个季度中有3个季度的每股收益超出预期,平均超出11.48% [1] 公司业务表现 生命科学业务 - 生物技术和生物制药终端市场持续疲软,对生命科学工具和生物加工产品的销售产生不利影响 [4] - 公司在中国市场需求疲软 [4] - 工艺色谱销售下降,反映了行业内的去库存趋势 [4] - 日本市场资金紧缩,欧洲主要市场也参差不齐 [4] - 但公司的Droplet Digital PCR (ddPCR)平台需求强劲,ddPCR试剂和耗材销售增长 [5] - 公司新推出的ChemiDoc成像系统和单细胞样品制备解决方案受到客户欢迎 [5] 临床诊断业务 - 质量控制免疫血液学和血型产品需求增加,带动该业务收入增长 [6] - 该业务在各地区均实现收入增长 [6] 财务表现 - 第三季度收入预计同比增长0.8%至639.9百万美元 [2] - 第三季度每股收益预计同比下降45.1%至1.28美元 [2] - 过去30天内,每股收益预测值下调40.2%至1.28美元 [3] - 公司目前的Zacks排名为4级,不具备战胜预期的条件 [8]

LAS VEGAS and HOLMDEL, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring phoneless, tokenless, passwordless and phish-resistant authentication solutions, announced the company will sponsor, speak, and exhibit at ISC2 Security Congress 2024, in Las Vegas on October 14 – 16, 2024. BIO-key will be hosting a session on Passkeys. Passkeys and zero trust are core enabling co ...